TargeGen puts its topical AMD candidate to the test
TargeGen has initiated a phase I trial of TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of age-related macular degeneration (AMD) and other degenerative eye diseases.
TargeGen has initiated a phase I trial of TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of age-related macular degeneration (AMD) and other degenerative eye diseases.
Applied in eye drop form, TG100801 is designed to suppress oedema, angiogenesis and inflammation. The company believes that the topical application will provide equal or superior efficacy compared with injectable agents while also providing greater convenience and safety advantages.
It is hoped that the single site phase I trial will be complete by the end of the first quarter of 2007 and that phase II trials will be initiated by mid 2007.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
